Ctrl

K

Acalabrutinib

Class
Targeted therapy
Subclass
Bruton tyrosine kinase inhibitors
Generic name
Acalabrutinib
Brand names
Calquence®
Common formulations
Gelatin-coated capsule
Dosage and administration
Adults patients
Chronic lymphocytic leukemia • Relapsed or refractory
•
100 mg PO BID until disease progression or unacceptable toxicity
Mantle cell lymphoma
•
100 mg PO BID until disease progression or unacceptable toxicity
Indications for use
Labeled indications
Adults
•
Treatment of chronic lymphocytic leukemia (relapsed or refractory)
•
Treatment of mantle cell lymphoma
Pregnancy and breastfeeding
Breastfeeding
Little information available on breastfeeding safety.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
•
Acute hemorrhage, anemia, contusion, ↓ blood neutrophil count, ↓ platelet count, ↑ blood lymphocyte count, lower respiratory tract infections, malignant neoplasm, repeated infections, abdominal pain, arthralgia, constipation, diarrhea, dizziness, fatigue, headache, myalgia, nausea, skin rash, vomiting, urinary tract infections, upper respiratory tract infections
Common 1-10%
•
Atrial arrhythmia, ↓ blood lymphocyte count, herpes simplex virus infection, hypertension, nosebleed, skin cancer
Unknown frequency
•
Opportunistic infections, pneumonia
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource